The novel treatment of the medication represents a major development in the handling of the condition. Different to existing therapies, tirzepatide impacts two pathways – glucagon-like peptide-1 (GLP-1) and GIP – leading to greater blood sugar control and anticipated reduction in weight. Experts are studying its potential advantages and role in